知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

25 records (took 0.022 seconds)

    Sustained release drug delivery devices
    13.
    发明授权
    Sustained release drug delivery devices 失效
    持续释放药物输送装置

    公开(公告)号：US5902598A

    公开(公告)日：1999-05-11

    申请号：US919221

    申请日：1997-08-28

    Applicant: Jianbing Chen ,  Paul Ashton

    Inventor： Jianbing Chen ,  Paul Ashton

    IPC: A61K9/00 ,  A61K9/22 ,  A61K9/32 ,  A61K31/455 ,  A61K31/52 ,  A61K31/58 ,  A61P27/02

    CPC classification number: A61K9/0092 ,  A61K9/0024 ,  A61K9/0051

    Abstract: A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir comprising the effective agent; a first coating layer, which is permeable to the passage of the effective agent; a second coating layer, which is essentially impermeable to the passage of the effective agent; and a third coating layer, which is permeable to the passage of the effective agent. The first coating layer covers at least a portion of the inner core. The second coating layer covers at least a portion of the first coating layer and inner core; however, at least a small portion of the first coating layer or inner core is not coated with the second coating layer. The second coating layer includes an impermeable film and at least one impermeable disc. The third coating layer essentially completely covers the second coating layer and the uncoated portion of the first coating layer or inner core.

    Abstract translation: 提供了一种用于治疗哺乳动物生物体以获得所需局部或全身生理或药理作用的方法和装置。 该方法包括向需要这种治疗的哺乳动物生物体施用持续释放药物递送系统，其中需要释放有效药剂并允许有效药剂以受控的方式通过该装置。 该装置包括一个包含有效试剂的内核或储存器; 第一涂层，其可渗透有效剂的通过; 第二涂层，其对于有效试剂的通过基本上是不可渗透的; 以及对有效药剂通过是可渗透的第三涂层。 第一涂层覆盖内芯的至少一部分。 第二涂层覆盖第一涂层和内芯的至少一部分; 然而，第一涂层或内芯的至少一小部分没有涂覆第二涂层。 第二涂层包括不渗透膜和至少一个不透水盘。 第三涂层基本上完全覆盖第二涂层和第一涂层或内芯的未涂覆部分。

    Porous silicon drug-eluting particles
    14.
    发明授权
    Porous silicon drug-eluting particles 有权
    多孔硅药物洗脱颗粒

    公开(公告)号：US09023896B2

    公开(公告)日：2015-05-05

    申请号：US12773127

    申请日：2010-05-04

    Applicant: Paul Ashton ,  Hong Guo ,  Jianbing Chen ,  Leigh Canham

    Inventor： Paul Ashton ,  Hong Guo ,  Jianbing Chen ,  Leigh Canham

    IPC: A61K47/02 ,  A61K9/14 ,  A61K9/00 ,  A61K31/58

    CPC classification number: A61K31/58 ,  A61K9/0048 ,  A61K9/0097

    Abstract: The invention provides a biodegradable drug-eluting particle useful for the delivery of diagnostic or therapeutic agents. In certain embodiments, the drug-eluting particle of the invention comprises a biodegradable porous silicon body, a reservoir formed within the porous silicon body having at least one opening to an exterior of the body, wherein the reservoir contains a therapeutic or diagnostic agent, and an agent-permeable seal disposed over the at least one opening. The invention further provides a method for treating a patient to obtain a desired local or systemic physiological or pharmacological effect comprising administering a sustained release drug delivery particle of the invention. The invention also provides methods of fabricating a drug-eluting particle for releasing therapeutic agents.

    Abstract translation: 本发明提供了可用于递送诊断或治疗剂的可生物降解的药物洗脱颗粒。 在某些实施方案中，本发明的药物洗脱颗粒包括可生物降解的多孔硅体，形成在多孔硅体内的储存器，其具有至少一个开口到本体的外部，其中储存器包含治疗剂或诊断剂，以及 设置在所述至少一个开口上方的渗透剂的密封件。 本发明进一步提供了一种治疗患者以获得所需局部或全身生理或药理作用的方法，包括施用本发明的缓释药物递送颗粒。 本发明还提供了制备用于释放治疗剂的药物洗脱颗粒的方法。

    Polymeric gel delivery system for pharmaceuticals
    18.
    发明申请
    Polymeric gel delivery system for pharmaceuticals 审中-公开
    用于药物的聚合物凝胶输送系统

    公开(公告)号：US20090010986A1

    公开(公告)日：2009-01-08

    申请号：US12229943

    申请日：2008-08-28

    Applicant: Paul Ashton ,  Jianbing Chen

    Inventor： Paul Ashton ,  Jianbing Chen

    IPC: A61F2/04 ,  A61K31/58 ,  A61K31/407 ,  A61P37/02 ,  A61K31/196 ,  A61K47/36

    CPC classification number: A61K9/0024 ,  A61K9/0019 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/205 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/55

    Abstract: Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint.

    Abstract translation: 当植入，注射，可插入或以其他方式施用的组合物在植入，注射，插入或施用于生物组织中或其上时形成水凝胶包含药学上有效的化合物，其中药学上有效的化合物是其药物或其药学上可接受的盐或前药的混合物 与水凝胶形成化合物。 药学上有效的化合物可以是可溶于体液的任何化合物，或当暴露于体液时形成体液可溶性加合物。 示例性化合物包括止痛剂，抗炎剂和抗生素化合物。 形成水凝胶的化合物是一种生物耐受物质，其在暴露于体液如围绕或在关节内的间质液体时形成水凝胶。

    POLYMERIC GEL DELIVERY SYSTEM FOR PHARMACEUTICALS
    19.
    发明申请
    POLYMERIC GEL DELIVERY SYSTEM FOR PHARMACEUTICALS 审中-公开
    用于药物的聚合物凝胶输送系统

    公开(公告)号：US20120195934A1

    公开(公告)日：2012-08-02

    申请号：US13370106

    申请日：2012-02-09

    Applicant: Paul Ashton ,  Jianbing Chen

    Inventor： Paul Ashton ,  Jianbing Chen

    IPC: A61K9/00 ,  A61K38/00 ,  A61K31/56 ,  A61K31/513 ,  A61K31/439 ,  A61P29/00 ,  A61P19/02 ,  A61P31/00 ,  A61P31/10 ,  A61P31/12 ,  A61P27/06 ,  A61P37/02 ,  A61P41/00 ,  A61P3/00 ,  A61P35/00 ,  A61K47/00

    CPC classification number: A61K9/0024 ,  A61K9/0019 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/205 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/55

    Abstract: Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint.

    Abstract translation: 当植入，注射，可插入或以其他方式施用的组合物在植入，注射，插入或施用于生物组织中或其上时形成水凝胶包含药学上有效的化合物，其中药学上有效的化合物是其药物或其药学上可接受的盐或前药的混合物 与水凝胶形成化合物。 药学上有效的化合物可以是可溶于体液的任何化合物，或当暴露于体液时形成体液可溶性加合物。 示例性化合物包括止痛剂，抗炎剂和抗生素化合物。 形成水凝胶的化合物是一种生物耐受物质，其在暴露于体液如围绕或在关节内的间质液体时形成水凝胶。

Patent Agency Ranking